BeOne Medicines (NASDAQ:ONC) Stock Price Down 3.6% on Insider Selling

Shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) were down 3.6% on Thursday after an insider sold shares in the company. The stock traded as low as $257.11 and last traded at $257.41. Approximately 165,301 shares changed hands during mid-day trading, a decline of 63% from the average daily volume of 442,271 shares. The stock had previously closed at $267.13.

Specifically, CEO John Oyler sold 3,174 shares of the company's stock in a transaction dated Monday, June 23rd. The stock was sold at an average price of $261.61, for a total value of $830,350.14. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Xiaodong Wang sold 2,007 shares of BeOne Medicines stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $265.50, for a total value of $532,858.50. The disclosure for this sale can be found here. In other news, COO Xiaobin Wu sold 1,363 shares of BeOne Medicines stock in a transaction dated Monday, June 23rd. The stock was sold at an average price of $260.00, for a total transaction of $354,380.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Analyst Upgrades and Downgrades

ONC has been the subject of a number of analyst reports. Bank of America upgraded shares of BeOne Medicines from a "neutral" rating to a "buy" rating and lifted their target price for the company from $207.00 to $320.00 in a research note on Monday, March 3rd. JMP Securities set a $348.00 price target on BeOne Medicines in a research note on Friday, February 28th. Macquarie raised their price objective on BeOne Medicines from $259.00 to $313.00 and gave the company an "outperform" rating in a research note on Friday, February 28th. Sanford C. Bernstein set a $259.00 price target on BeOne Medicines in a report on Thursday, March 13th. Finally, Wall Street Zen upgraded shares of BeOne Medicines from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $319.00.

BeOne Medicines Price Performance

The firm has a market cap of $28.24 billion, a PE ratio of -69.27 and a beta of 0.30. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.71 and a current ratio of 1.96. The stock has a 50 day simple moving average of $247.22.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of ($0.71) by $1.93. The company had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.12 billion. BeOne Medicines had a negative return on equity of 7.55% and a negative net margin of 9.40%. As a group, analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current year.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.